

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

- 1-30. (canceled).
31. (previously presented) An isolated monoclonal antibody MJ-170 produced by hybridoma cell line MJ-170 on deposit with the American Type Culture Collection (ATCC) as accession number PTA-5286.
32. (previously presented) An isolated monoclonal antibody MJ-171 produced by hybridoma cell line MJ-171 on deposit with the ATCC as accession number PTA-5287.
33. (previously presented) An isolated monoclonal antibody MJ-172 produced by hybridoma cell line MJ-172 on deposit with the ATCC as accession number PTA-5288.
34. (previously presented) An isolated monoclonal antibody MJ-173 produced by hybridoma cell line MJ-173 on deposit with the ATCC as accession number PTA-5302.
35. (previously presented) A hybridoma cell line MJ-170 on deposit with the ATCC as accession number PTA-5286.
36. (previously presented) A hybridoma cell line MJ-171 on deposit with the ATCC as accession number PTA-5287.
37. (previously presented) A hybridoma cell line MJ-172 on deposit with the ATCC as accession number PTA-5288.
38. (previously presented) A hybridoma cell line MJ-173 on deposit with the ATCC as accession number PTA-5302.
39. (canceled).
40. (previously presented) An antibody of claim 31, 32, 33 or 34, wherein said antibody is covalently linked to a cytotoxic agent or a prodrug of a cytotoxic agent.
41. (previously presented) The antibody of claim 40, wherein said cytotoxic agent is a small drug molecule.

42. (previously presented) The antibody of claim 40, wherein said cytotoxic agent is a maytansinoid, a taxoid, or a CC-1065 analog.

43. (original) A composition comprising an antibody of claim 31, 32, 33 or 34 and a pharmaceutically acceptable carrier.

44. (previously presented) A composition comprising the antibody of claim 40 and a pharmaceutically acceptable carrier.

45. (withdrawn) A method of treating a subject having a cancer, comprising administering to a subject having a cancer a therapeutically effective amount of the composition of claim 43.

46. (withdrawn) A method of treating a subject having a cancer, comprising administering to a subject having a cancer a therapeutically effective amount of the composition of claim 44.

47-48. (canceled).

49. (withdrawn) The method of claim 45, wherein said cancer is a cancer wherein Muc1 or Muc16 is overexpressed.

50. (withdrawn) The method of claim 46, wherein said cancer is a cancer wherein Muc1 or Muc16 is overexpressed.

51. (withdrawn ) The method of claim 45, wherein said cancer is ovarian cancer or breast cancer.

52. (withdrawn ) The method of claim 46, wherein said cancer is ovarian cancer or breast cancer.

53. (previously presented) An isolated antibody that specifically binds to a Muc1 peptide selected from the group consisting of:

- a) QLTLAFREGTINVHDTVETQFN (SEQ ID NO:8);
- b) QYKTEAASRYNLTISDVSVSD (SEQ ID NO:9);
- c) FLQIYKQGGFLGLSNIKFRPG (SEQ ID NO:10); and
- d) VPPFSAQSGAGVPGWGIA (SEQ ID NO:12).

54. (previously presented) An isolated antibody that specifically binds to a Muc16 peptide selected from the group consisting of:

- a) SSVLVDGYSPNRNEPLTGNS (SEQ ID NO:14);
- b) TNYQRNKRNIEDALNQLFRN (SEQ ID NO:15);
- c) FRNSSIKSYFSDCQVSTFRSV (SEQ ID NO:16);
- d) SVPNRHHTGVDSL CNFSPLARRV (SEQ ID NO:17); and
- e) DRVAIYEEFLRMTRNGTQLQNFTLDRSS (SEQ ID NO:18).

55. (currently amended) The antibody of claim 53 or 54, wherein said antibody is selected from the group consisting of a monoclonal antibody, a recombinant antibody, an antigen-binding ~~a~~-fragment of a recombinant antibody, a humanized antibody, and an antibody displayed upon the surface of a phage.

56. (previously presented) The antibody of claim 53 or 54, wherein said antibody is covalently linked to a cytotoxic agent or a prodrug of a cytotoxic agent.

57. (previously presented) The antibody of claim 56, wherein said cytotoxic agent is a small drug molecule.

58. (previously presented) The antibody of claim 56, wherein said cytotoxic agent is a maytansinoid, taxoid, or CC-1065 analog.

59. (previously presented) A composition comprising the antibody of claim 53 or 54 and a pharmaceutically acceptable carrier.

60. (previously presented) A composition comprising the antibody of claim 56 and a pharmaceutically acceptable carrier.

61. (withdrawn) A method of treating a subject having a cancer, comprising administering to a subject having a cancer a therapeutically effective amount of the composition of claim 59.

62. (withdrawn) A method of treating a subject having a cancer, comprising administering to a subject having a cancer a therapeutically effective amount of the composition of claim 60.

63. (withdrawn) The method of claim 61, wherein said cancer is a cancer wherein Muc1 or Muc16 is overexpressed.

64. (withdrawn) The method of claim 62, wherein said cancer is a cancer wherein Muc1 or Muc16 is overexpressed.

65. (withdrawn) The method of claim 61 or 62, wherein said cancer is ovarian cancer or breast cancer.

66. (withdrawn) A method of screening a subject for cancer, comprising:

(a) measuring the amount of Muc1 in a biological sample obtained from a subject using the antibody of claim 53; and

(b) comparing the amount of Muc1 measured in (a) to the amount of Muc1 in a cancerous and a non-cancerous control, thereby screening a subject for cancer.

67. (withdrawn) A method of screening a subject for cancer, comprising:

(a) measuring the amount of Muc16 in a biological sample obtained from a subject using the antibody of claim 54; and

(b) comparing the amount of Muc16 measured in (a) to the amount of Muc16 in a cancerous and a non-cancerous control, thereby screening a subject for cancer.

68. (withdrawn) The method of claim 66 or 67, wherein said cancer is ovarian cancer or breast cancer.

69-70. (canceled).

71. (previously presented) A hybridoma that produces an antibody that specifically binds to a MUC1 peptide selected from the group consisting of:

- a) QLTLAFREGTINVHDTVETQFN (SEQ ID NO:8);
- b) QYKTEAASRYNLTISDVSVSD (SEQ ID NO:9);
- c) FLQIYKQGGFLGLSNIKFRPG (SEQ ID NO:10); and
- d) VPFPSAQSGAGVPGWGIA (SEQ ID NO:12).

72. (previously presented) A hybridoma that produces an antibody that specifically binds to a MUC16 peptide selected from the group consisting of:

- a) SSVLVDGYSPNRNEPLTGNS (SEQ ID NO:14);
- b) TNYQRNKRNIEDALNQLFRN (SEQ ID NO:15);
- c) FRNSSIKSYFSDCQVSTFRSV (SEQ ID NO:16);
- d) SVPNRHHTGVDSL CNFSPLARRV (SEQ ID NO:17); and
- e) DRVAIYEEFLRMTRNGTQLQNFTLDRSS (SEQ ID NO:18).